- Conditions
- Marginal Zone Lymphoma, MZL
- Interventions
- Zanubrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Westbury, New York • Charlotte, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 131
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cholesterol, Hyperlipidemia, Hypercholesteremia
- Interventions
- Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions
- Dietary Supplement · Other
- Lead sponsor
- Integrative Health Technologies, Inc.
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Participants
- Interventions
- BMS-986278 Tablet, Esomeprazole, BMS-986278 suspension
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV Infections
- Interventions
- maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- CC-220, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more
- Conditions
- Crohn's Disease
- Interventions
- Growth Hormone, Nutraceutical Combination, Exclusion Diet, Placebo Growth Hormone
- Drug · Dietary Supplement · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 10 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypogonadism
- Interventions
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Antonio, Texas
- Conditions
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- lenvatinib, everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Ezetimibe, Placebo (for Alirocumab), Placebo (for Ezetimibe)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia
- Conditions
- Uncomplicated Urinary Tract Infections
- Interventions
- Pivya (Pivmecillinam 185 mg), Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule)
- Drug
- Lead sponsor
- Alembic Therapeutics
- Industry
- Eligibility
- 12 Years to 17 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dearborn Heights, Michigan
- Conditions
- HIV Infections
- Interventions
- darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc, Raltegravir, Ritonavir 100 mg
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Bacterial Vaginosis, Yeast Infection
- Interventions
- Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
- Dietary Supplement
- Lead sponsor
- Happy V
- Industry
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Psychological Stress, Sleep Disturbance, Anxiety Symptoms, Depressive Symptoms, Occupational Burnout
- Interventions
- Neuralli Mood
- Dietary Supplement
- Lead sponsor
- Efforia, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Amino Acid Absorption, Probiotic
- Interventions
- Single Strain Probiotic + Milk Protein, Placebo + Milk Protein
- Dietary Supplement
- Lead sponsor
- The Archer-Daniels-Midland Company
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Belton, Texas
- Conditions
- Healthy Volunteers
- Interventions
- BLU-782, Placebo, BLU-782 taken with food
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Healthy
- Interventions
- Calderasib, PPI
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Adenomatous Polyps
- Interventions
- 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy
- Drug · Procedure
- Lead sponsor
- Colotech A/S
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
- Interventions
- Enzalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 79
- States / cities
- Duarte, California • Fullerton, California • Irvine, California + 49 more
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease
- Interventions
- : Placebo for Probiotic, Lactobacillus Rhamnosus GG
- Drug · Dietary Supplement
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab, Tazemetostat Pill, Capivasertib
- Drug
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- Hypertriglyceridemia
- Interventions
- Epanova, Olive Oil
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more
- Conditions
- Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Budesonide EC, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah